| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -5,000 | -3,244 | -15,402 | - |
| Change in fair value of warrant liability | - | 0 | 0 | - |
| Change in fair value of forward contract liability | - | 0 | 0 | - |
| Commitment fee payable | - | - | 0 | - |
| Other assets | - | 0 | 0 | 48 |
| Payable to parent | - | 0 | 0 | - |
| Change in fair value of sepa put option liability | 54 | 329 | 23 | - |
| Change in fair value of convertible debt | 0 | -810 | -846 | -117 |
| Commitment fee expense | - | 0 | - | - |
| Gain on termination of warrant and commitment fee liabilities | - | 0 | - | - |
| Non-cash discount on convertible debt | - | 0 | 625 | - |
| Stock-based compensation expense | 694 | 702 | 704 | 1,280 |
| Amortization of operating lease right-of-use asset | 171 | 168 | 166 | 254 |
| Depreciation expense | 66 | 66 | 65 | 113 |
| Prepaid expenses | -435 | 1,082 | -960 | 1,108 |
| Accounts payable and accrued expenses | -95 | -124 | -732 | -646 |
| Other current assets | 403 | 0 | 0 | -18 |
| Operating lease liability | -178 | -130 | -170 | -250 |
| Net cash used in operating activities | -4,364 | -3,163 | -3,972 | -9,259 |
| Purchases of property and equipment | 0 | 0 | 6 | 256 |
| Net cash used in investing activities | 0 | 0 | -6 | -256 |
| Proceeds from short-term convertible debt | - | 4,375 | - | - |
| Proceeds from short-term borrowing | - | -4,375 | 0 | 4,375 |
| Repayments of short-term borrowing | - | 0 | 0 | 0 |
| Proceeds from loan payable | 327 | - | - | - |
| Repayments of short-term convertible debt | - | 3,400 | - | - |
| Repayments of loan payable | 81 | - | - | - |
| Proceeds from issuance of common stock, net of direct costs | 706 | 6,590 | 0 | 0 |
| Net cash provided by financing activities | 952 | 3,190 | 0 | 4,375 |
| Net decrease in cash and cash equivalents | -3,412 | 27 | -3,978 | -5,140 |
| Cash and cash equivalents, beginning of period | 4,894 | 4,867 | 13,985 | - |
| Cash and cash equivalents, end of period | 1,482 | 4,894 | 4,867 | - |
FibroBiologics, Inc. (FBLG)
FibroBiologics, Inc. (FBLG)